

Resource Summary Report

Generated by [dkNET](#) on Sep 18, 2026

BALB/cAnNCrI

RRID:MGI:2683685

Type: Organism

Proper Citation

RRID:MGI:2683685

Organism Information

URL: <http://www.informatics.jax.org/strain/MGI:2683685>

Proper Citation: RRID:MGI:2683685

Description: laboratory mouse with name BALB/cAnNCrI from MGI.

Species: laboratory mouse

Notes: Strain Type: inbred strain

Catalog Number: 2683685

Database: Mouse Genome Informatics MGI

Database Abbreviation: MGI

Availability: Availability unknown check source stock center

Organism Name: BALB/cAnNCrI

Record Creation Time: 20230227T022110+0000

Record Last Update: 20260912T215257+0000

Ratings and Alerts

No rating or validation information has been found for BALB/cAnNCrI.

No alerts have been found for BALB/cAnNCrI.

Data and Source Information

Source: [Integrated Animals](#)

Usage and Citation Metrics

We found 66351 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kassegn TA, et al. (2026) NAD⁺ Homeostasis Attenuates Japanese Encephalitis Virus Infection Progression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(4), e71526.

Liu L, et al. (2026) PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma. Cell death & disease, 17(1), 19.

Zhu M, et al. (2026) GFAT2-mediated HSPD1 O-GlcNAcylation drives chemotherapy resistance in non-small cell lung cancer. Journal of experimental & clinical cancer research : CR, 45(1).

Zhang Y, et al. (2026) Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. Biochemical pharmacology, 249, 117904.

Wu SY, et al. (2026) Secretory autophagy mediates SLC16A3/MCT4-dependent lactate secretion to drive metastatic progression in triple-negative breast cancer. Autophagy, 22(7), 1560.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and $\alpha 5 \beta 1$ Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. Cancer research, 86(1), 99.

Liu F, et al. (2026) SPAC: a scalable and integrated enterprise platform for single-cell spatial analysis. BMC bioinformatics, 27(1), 25.

Ding Z, et al. (2026) TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma. Cancer research, 86(14), 3436.

Wu J, et al. (2026) A Noncanonical RNA-Binding Function of NQO1 Drives Angiogenesis in Esophageal Squamous Cell Carcinoma via Extracellular Vesicle-Mediated AGRN Transfer. Cancer research, 86(12), 2951.

Zhu X, et al. (2026) Ferroptosis-STING co-activation drives GzmB⁺CD38⁺CD8⁺ T-cell expansion to overcome lymphoma immunosuppression. Biomaterials, 334, 124250.

Zhang Y, et al. (2026) Targeted tumor starvation strategy augments radiosensitivity and enhances radioactive iodine-mediated tumor immunotherapy. Acta pharmacologica Sinica, 47(7), 1955.

Mogi M, et al. (2026) Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture. British journal of cancer, 134(1), 141.

Luo Y, et al. (2026) piR-1170 drives brain metastasis and immune evasion via WTAP-mediated m6A methylation reprogramming in triple-negative breast cancer. *Molecular cancer*, 25(1).

Niravath P, et al. (2026) A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1697.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. *Cancer research*, 86(8), 2024.

Wang H, et al. (2026) ZNF296 Drives Immune Evasion in Epithelial Cancers by Repressing Immune Stimulatory Genes. *Cancer research*, 86(1), 116.

Tran U, et al. (2026) BICC1 interacts with PKD1 and PKD2 to drive cystogenesis in ADPKD. *eLife*, 14.

Zhang X, et al. (2026) Synergistic mechanical and therapeutic modulation of engineered tumor cell-derived microparticles for enhanced cancer treatment. *Cell reports. Medicine*, 7(2), 102591.

Sun Y, et al. (2026) Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma. *Cancer research*, 86(12), 2970.

Blackman SA, et al. (2026) Antibodies blocking PIGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. *The Journal of biological chemistry*, 302(6), 111476.